STAT

Lilly’s next-gen obesity drug delivers major weight loss in Phase 3 trial, but with many discontinuations

Eli Lilly's next-gen obesity drug delivered major weight loss in a trial, but some patients stopped using it after losing too ...
STAT

Pharmalittle: We’re reading about Lilly’s new obesity drug, E.U. pharma rules, and much more

Eli Lilly’s next-generation obesity drug led to what appears to be the most weight loss seen so far in a late-stage trial, ...

Lilly's next-gen drug shows greater weight loss than Zepbound in late-stage trial

Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...

Major Weight Loss and Knee-Pain Relief Seen With New Eli Lilly Drug

The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug.
MarketWatch

Pfizer won its fight to buy an obesity-drug maker. It took an extra $1.7 billion and a phone call.

Pfizer Inc. pulled off a comeback win, beating out Danish drug giant Novo Nordisk to acquire obesity drug developer Metsera Inc. in a deal that values the biotechnology company at up to $9.1 billion.